Uridine triacetate

Drug Overview:

Uridine triacetate is an oral prodrug of uridine, a nucleoside, used as a specific emergency antidote for the life-threatening toxicities of two chemotherapeutic agents: fluorouracil (5-FU) and capecitabine. It is not a chemotherapeutic or anti-cancer drug itself.

• Generic Name: Uridine triacetate
• US Brand Name: Vistogard®
• Drug Class: Metabolic Rescue Agent / Antidote
• Route of Administration: Oral (granules)
• FDA Approval Status: Approved for the emergency treatment of adult and pediatric patients following:

1. An overdose of fluorouracil (5-FU) or capecitabine, regardless of the presence of symptoms.
2. Early-onset, severe or life-threatening toxicities affecting the cardiac or central nervous systems, and/or early onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity, neutropenia) within 96 hours after the end of fluorouracil or capecitabine administration.

What Is It and How Does It Work? (Mechanism of Action):

Uridine triacetate is an emergency rescue agent that works by a “biochemical bypass” mechanism to counteract the severe, potentially fatal toxicity of fluoropyrimidine chemotherapy (5-FU/capecitabine).

• Molecular Target: It does not target a receptor or pathway. Instead, it provides a high systemic concentration of uridine, a natural pyrimidine nucleoside.
• Cellular Impact: The anti-cancer effect and toxicity of 5-FU are primarily mediated by its metabolite, fluorodeoxyuridine monophosphate (FdUMP), which irreversibly inhibits the enzyme thymidylate synthase (TS), halting DNA synthesis. In overdose or cases of heightened sensitivity, this inhibition becomes catastrophic. Orally administered uridine triacetate is rapidly converted to uridine in the body. Uridine is phosphorylated to uridine triphosphate (UTP), which competes with and dilutes the toxic fluorinated nucleotides (e.g., FUTP) that get incorporated into RNA, causing RNA dysfunction and cell damage.
• Result: The massive influx of uridine provides substrate to bypass the blocked TS enzyme via the salvage pathway, allowing for the resumption of DNA synthesis and cell viability in healthy tissues. It also competitively reduces the incorporation of 5-FU metabolites into RNA. This action mitigates or prevents the progression of severe toxicities in the gastrointestinal tract, bone marrow, and nervous system.
• Rescue Agent: Uridine triacetate is a specific metabolic antidote. It is a critical component of emergency preparedness in clinics administering fluoropyrimidine chemotherapy.

FDA Approved Clinical Indications:

• Non-Oncological Use (As an Antidote):
  • Emergency treatment of overdose with fluorouracil or capecitabine.
  • Emergency treatment of early-onset, severe or life-threatening toxicity affecting cardiac or central nervous systems, and/or early onset, unusually severe adverse reactions within 96 hours after the end of fluorouracil or capecitabine administration.
• Oncological Uses:
  • Uridine triacetate has no direct anti-cancer indications. Its sole purpose is to rescue patients from the toxicity of fluoropyrimidine chemotherapy.

Dosage and Administration Protocols:

Treatment must be initiated as soon as possible after overdose or recognition of severe toxicity, ideally within 96 hours. It is administered orally in repeated doses.

Dosage and Administration Protocols:

Uridine triacetate is critical as an emergency intervention, requiring prompt administration within a strict time window to be effective.

Renal and Hepatic Dose Adjustments

• Renal and Hepatic Insufficiency: No specific dosage adjustments are typically required for patients with renal or hepatic impairment. However, since the drug is used in an emergency setting, close clinical monitoring and supportive care for organ function are essential.
• Administration: The granules can be mixed with soft foods (like applesauce, yogurt, or pudding) or water and must be consumed immediately after mixing.

Clinical Efficacy and Research Results:

The efficacy of uridine triacetate is supported by retrospective and expanded access treatment data, as prospective placebo-controlled trials in overdose scenarios are not ethical.

• Survival in Overdose: In a published case series of patients who received uridine triacetate for 5-FU overdose (≥ 1.5 times standard dose), survival was 96% (43 of 45 patients). Historical mortality from such overdoses without rescue therapy is exceedingly high.
• Mitigation of Severe Toxicity: In patients with severe, early-onset toxicity following standard-dose 5-FU/capecitabine (e.g., due to dihydropyrimidine dehydrogenase (DPD) deficiency), timely administration of uridine triacetate has been associated with rapid reversal of neurological symptoms, stabilization of cardiac function, and prevention of progression to fatal mucositis and myelosuppression.
• Contemporary Context (2020-2025): Current focus is on improving pre-treatment screening for DPD deficiency to prevent toxicity. Uridine triacetate remains the established, life-saving rescue standard. Recent studies and guidelines reinforce its essential role in institutional safety protocols for fluoropyrimidine administration.

Safety Profile and Side Effects:

Black Box Warning:

• None for uridine triacetate.

Common Side Effects (>10%):

• Gastrointestinal: Vomiting, nausea, diarrhea.
• Other: Headache, fever.

Management Strategies:

• Vomiting: If vomiting occurs within 2 hours of a dose, a replacement dose should be administered. Antiemetics may be used.
• Diarrhea/Headache: Managed with supportive care (hydration, analgesics). The benefits of continuing rescue therapy far outweigh these side effects in the context of life-threatening 5-FU toxicity.

Serious Adverse Events

• No specific serious adverse events directly attributable to uridine triacetate have been identified that outweigh the mortal risk of untreated fluoropyrimidine overdose/toxicity. The primary serious “adverse event” would be failure to administer it promptly when indicated.

Research Areas:

Research involving uridine triacetate is limited, as its role as a rescue agent is well-defined. Current investigation in fluoropyrimidine toxicity focuses upstream on pharmacogenomic testing (e.g., for DPD, TYMS, ENOSF1 gene variants) to identify high-risk patients before chemotherapy begins, thereby preventing toxicity and the need for rescue. There is no active research combining uridine triacetate with stem cell therapies, regenerative medicine, or immunotherapy.

Patient Management and Practical Recommendations:

Pre-treatment (of Chemotherapy):

• DPD Testing: Consider pre-emptive screening for DPD deficiency before initiating 5-FU or capecitabine to identify high-risk patients.
• Emergency Protocol: Institutions must have an immediate-access protocol for uridine triacetate.

Precautions During Treatment (with Uridine Triacetate):

• Timing is Critical: Initiate within 96 hours of the inciting fluoropyrimidine dose. Every hour of delay reduces efficacy.
• Dosing Adherence: Complete the full 20-dose regimen over 5 days as prescribed, even if symptoms improve.
• Vomiting Management: Have a plan for administering a replacement dose if vomiting occurs.

Do’s and Don’ts (For Healthcare Providers & Patients/Families):

• DO have uridine triacetate readily available in any facility administering 5-FU or capecitabine.
• DO initiate treatment IMMEDIATELY upon suspected overdose or early severe toxicity do not wait for confirmatory tests.
• DO complete the full 5-day course of therapy.
• DON’T delay administration. Early intervention is the single most important factor for survival.
• DON’T confuse this with an anti-cancer treatment. It is strictly an antidote.
• DON’T administer future cycles of fluoropyrimidine chemotherapy to a patient who requires rescue with uridine triacetate without a thorough re-evaluation of dosing and DPD status.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved emergency use and key information for uridine triacetate and is not a substitute for professional medical advice. The management of chemotherapy overdose and toxicity is a medical emergency requiring immediate intervention by qualified healthcare providers. Always follow institutional emergency protocols and consult with a clinical toxicologist or oncologist.